| Patient | Gilda Radner |
|---|---|
| Date of birth | 1986-06-28 |
| Identifiers | MRN HR-ML026-SYN; SSN (made up) 000-26-8821 |
| Document date | 2026-10-13 |
| Author | Delia Marchand, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit, four weeks into olaparib. [S]
Ms. Radner, now 40, comes for her yearly preventive visit four weeks after starting olaparib maintenance. She finished six cycles of carboplatin and paclitaxel seven weeks ago; the end-of-treatment CT showed no evidence of disease and her CA-125 was 9. On olaparib she has mild nausea in the first hour after the morning dose, which settles if she takes it with food, and she tires in the late afternoon. She has no breathlessness, cough, fever, or bruising. The tingling in her toes is fading. Hot flashes wake her two or three nights a week; she has chosen to wait on hormone therapy for now. She goes to a support group at a cancer support community every other week and is writing again. Her PHQ-9 today is 2. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 40 |
| Active conditions | Stage IIIC high-grade serous ovarian cancer, no evidence of disease after surgery and chemotherapy; on olaparib for four weeks |
| Medicines | Olaparib 300 mg twice daily; ondansetron when needed, used twice this month |
| Olaparib effects | Mild morning nausea, afternoon tiredness; no breathlessness or bruising |
| Menopause | Hot flashes two or three nights a week; hormone therapy deferred by her choice |
| Mood | PHQ-9 2; attends a support group |
Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Marchand. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good and improving |
| Psychosocial | Supported by her spouse and friends; a support group every other week; back to writing and some work |
| Tobacco | Never smoked |
| Alcohol and drugs | A glass of wine on some weekends (AUDIT-C 1); no drugs |
| Physical activity | Walks 30 minutes most days; building up after treatment |
| Nutrition | Three small meals and snacks; appetite back; weight up 1.4 kg since the end of chemotherapy |
| Sleep | Six to seven hours, broken by hot flashes two or three nights a week |
| Sexual health | Vaginal dryness since surgery; using a moisturizer |
| Safety at home | Feels safe; no one hurts, threatens, or controls her; no firearm in the home |
| Road safety | Wears a seat belt |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon tiredness; no fever, night sweats, or weight loss |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | No mouth sores or hearing change |
| Cardiovascular | Negative | No chest pain, palpitations, or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Mild nausea after the morning dose; no bloating, early fullness, or change in bowel habit |
| Genitourinary | Positive | Vaginal dryness; no urinary symptoms or vaginal bleeding |
| Musculoskeletal | Negative | No joint or bone pain |
| Integumentary | Negative | Hair growing back; no rash or bruising |
| Neurological | Positive | Slight tingling in the toes, fading; no weakness or falls |
| Endocrine | Positive | Hot flashes two or three nights a week |
| Psychiatric | Negative | Mood good; PHQ-9 2; no thoughts of self-harm |
| Hematologic and lymphatic | Negative | No bruising, bleeding, or swollen glands |
13 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery | 40 mg under the skin once daily for 28 days | Subcutaneous route | 2026-04-21 to 2026-05-18 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-04-21 to 2026-05-05 | completed | S |
| Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-05-12 to 2026-08-25 | completed | S |
| Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 2026-05-12 to 2026-08-25 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 2026-05-12 | active | S |
| Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two years | Two tablets twice daily with food | Oral route | 2026-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-13 | Body height | 160 | cm | S |
| 2026-10-13 | Body weight | 57.2 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 74 | /min | S |
| 2026-10-13 | Respiratory rate | 14 | /min | S |
| 2026-10-13 | Body temperature | 36.6 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-13 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 11.6-15 g/dL | Low | S |
| 2026-10-13 | Leukocytes [#/volume] in Blood by Automated count | 4.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-13 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-10-13 | Platelets [#/volume] in Blood by Automated count | 182 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-13 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-10-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-10-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 108 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-13 | Triglyceride [Mass/volume] in Serum or Plasma | 98 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-10-13 | Total score [AUDIT-C] | 1 | {score} | S |
Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 57.2 kg, BMI 22.3; blood pressure 112/70 |
| Head, eyes, ears, nose, and throat | No mouth ulcers; short regrowing hair |
| Neck | Thyroid normal; no lymph nodes |
| Breasts | No mass, skin change, or nipple discharge on either side; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur; no leg swelling |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Midline scar healed; soft, non-tender, no mass, no fluid |
| Lymph nodes | No cervical, supraclavicular, axillary, or inguinal nodes |
| Neurological | Light touch slightly reduced over the tips of the toes; vibration sense and ankle reflexes normal; steady gait |
| Skin | No rash, bruising, or suspicious lesions |
| Psychiatric | Bright and funny; organized; engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the week | resolved | confirmed | R19.00 | S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation. |
| High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian cancer | active | confirmed | C56.3 | S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D). |
| Peritoneal and omental metastases of the ovarian cancer, with ascites | active | confirmed | C78.6 | S — Synthetic extent of disease on CT and biopsy. |
| Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is known | active | confirmed | Z80.41 | S — Synthetic coding of her documented family history; the basis for genetic counseling. |
| Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic acute infection; not a historical claim. |
| Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweats | active | confirmed | E89.41 | S — Synthetic consequence of the synthetic operation. |
| Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities) | active | confirmed | G62.0 | S — Synthetic common effect of paclitaxel. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 112/70 mmHg |
| Depression screening | Completed today | PHQ-9 score 2; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 1 |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Breast cancer screening | Ordered | Screening mammogram every two years from 40; first one ordered today. Her germline panel was negative, so no extra breast imaging is needed for a variant |
| Cervical cancer screening | Not indicated | Cervix removed at a hysterectomy for ovarian cancer, with no history of cervical precancer |
| Colorectal cancer screening | Not indicated | Starts at 45; no family history of bowel cancer; Lynch syndrome genes negative on her panel |
| Cholesterol screening and statin decision | Completed today | Total cholesterol 186, HDL 58, LDL 108 mg/dL; ten-year risk under 2 percent; no statin |
| Diabetes screening | Not indicated | BMI 22.3 with no other risk factor |
| Osteoporosis screening | Ordered | Postmenopausal after surgery at 39, so a baseline bone density scan is reasonable |
| Hepatitis B, hepatitis C and HIV screening | Up to date | All negative before chemotherapy |
| Ovarian cancer screening | Not indicated | Screening is for women without symptoms; she is under cancer surveillance with gynecologic oncology |
| Influenza vaccine | Completed today | Inactivated vaccine given |
| COVID-19 vaccine | Completed today | This season's mRNA vaccine given |
| Pneumococcal vaccine | Completed today | PCV20 given, for an adult under 50 after cancer chemotherapy |
| Recombinant zoster vaccine | Completed today | Dose 1 given, for an adult under 50 after cancer chemotherapy; dose 2 in two to six months |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap five years ago |
| Live vaccines (MMR, varicella) | Not indicated | Immune from childhood doses; live vaccines are avoided within three months of chemotherapy |
| Dental examination | Due | Last visit before chemotherapy; to book a cleaning now that counts have recovered |
Immunizations given today: Influenza vaccine, this season (inactivated); COVID-19 mRNA vaccine, this season's formula; Pneumococcal conjugate vaccine (PCV20); Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Mammogram and bone density scan within the month. Blood count in four weeks. Gynecologic oncology review in about five weeks. Second zoster dose in two to six months. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here. She said that she wants to be told the truth about her illness plainly and in person, that she would want treatment aimed at living longer as long as she can still enjoy her days and be herself, and that if that were no longer possible she would want comfort and to be awake enough to know the people around her. She completed a health care proxy form and will think about a written living will. To be revisited at each change in her health and at least yearly. [S]